Whalesbook
Ab asli baat yeh hai ki yeh jo ₹100 crore ka naya fund aa raha hai, yeh TII ki taraf se ₹75 crore aur company ke CEO N Govindarajan ki taraf se ₹25 crore Compulsorily Convertible Preference Shares (CCPS) ke zariye aaega. Iska main reason hai 3xper ki CDMO (Contract Development and Manufacturing Operations) capabilities ko aur strong karna aur expand karna.
Yeh koi pehli baar nahi hai; TII ne March 2023 mein hi ₹285 crore ka initial plan announce karke pharma sector mein kadam rakha tha. Jab yeh latest ₹100 crore investment announce hua, April 23, 2026 ko, toh TII ka share price toh practically 4.82% upar bhaga, ₹3,024.40 ke level par trade ho raha tha. Market mein bhi is news kaafi positive response mila, derivatives mein bhi open interest badhta dikha.
Industry ke trend ki baat kare toh, Indian CDMO market ekdum booming hone wala hai. Estimates ke hisab se, yeh 2030 tak USD 20 billion tak ja sakta hai, aur kuch analysts ka kehna hai ki 2033/2034 tak yeh USD 16.53 billion se USD 55.5 billion ke beech hoga, with 7.39% to 13.2% tak ka CAGR. Global outsourcing badhne aur India ke cost advantages iske main drivers hain.
Par bhai, har sikke ke do pehlu hote hain. TII ka valuation P/E ratio ke hisab se kaafi high hai, lagbhag 41.14 se 93.41 tak. Iska matlab future mein bade returns expect kiye ja rahe hain. Aur 3xper khud bhi ekdum naya hai, FY25 mein revenue sirf ₹6.46 crore tha. Competition mein Lonza, WuXi AppTec jaise global giants aur Piramal Pharma, Divi's Labs jaise Indian players hain. Industry mein strict regulations aur quality control bhi bohot important hain.
N Govindarajan, jinhone pehle Aurobindo Pharma mein kaam kiya hai, unke experience se company ko madad milegi. Lekin ek successful CDMO business build karna ek bada challenge hai. Analysts ne iske liye ₹3,571.50 tak ka target set kiya hai, par near-term margins par pressure reh sakta hai. Overall, Murugappa Group ke liye yeh pharma mein ek important diversification move hai, jisme execution bohot critical hoga.